96866-14-7

Upstream product

• 5669-19-2 2-Benzyl-2-propenoic acid 
• 622-33-3 N-benzyloxyamine 

Downstream Products

• 223532-07-8 2-(benzyloxyamino-methyl)-3-phenyl-propionic acid methyl ester 
• 96866-15-8 3(RS)--2-benzylpropanoic acid 
• 1000393-31-6 2-[(benzyloxy-formyl-amino)-methyl]-3-phenyl-propionic acid methyl ester 

Relevant academic research and scientific papers

N-formyl hydroxylamine containing compounds useful as ACE inhibitors and/or NEP inhibitors

N-formyl hydroxylamines are provided which have the structure wherein R is H, alkyl, alkenyl, aryl-(CH2)p—, heteroaryl-(CH2)p— or cycloheteroalkyl-(CH2)p— R1is H or COR2where R2is alkyl, aryl-(CH2)p—, cycloheteroalkyl-(CH2)p—, heteroaryl-(CH2)p—, alkoxy or cycloalkyl-(CH2)p—, p is 0 to 8, and A is a dipeptide derived from an amino acid or is a conformationally restricted dipeptide mimic. The above compounds are useful in treating hypertension congestive heart failure, renal failure, and hepatic cirrhosis.

N-formyl hydroxylamine derivatives as antibacterial agents

Compounds of formula (I) are in the preparation of antibacterial agents, wherein: R1represents hydrogen, C1-C6alkyl or C1-C6alkyl substituted by one or more halogen atoms; R2represents a group R10(X)n—(ALK)— wherein R10represents hydrogen, a C1-C6alkyl, C2-C6alkenyl, C1-C6alkynyl, cycloalkyl, aryl, or heterocyclyl group, any of which may be unsubstituted or substituted by (C1-C6)alkyl, (C1-C6)alkoyy, hydroxy, mercapto, (C1-C6)alkylthio, amino, halo, trifluoromethyl, cyano, nitro, —COOH, —CONH2, —COORA, —NHCORA, —CONHRA, —NHRA, —NRARB, or —CONRARBwherein RAand RBare independently a (C1-C6)alkyl group, and ALK represents a straight or branched divalent C1-C6alkylene, C2-C6alkenylene, or C2-C6alkynylene radical, which may be interrupted by one or more non-adjacent —NH—, —O— or —S— linkages, X represents —NH—, —O— or —S—, and n is 0 or 1, R represents hydrogen or C1-C6alkyl, R3represents the characterising group or a natural or non-natural α amino acid in which any functional groups may be protected; and R4represents an ester or thioester group.

Cytostatic agents

Compounds of formula (I) wherein R4 is an ester or thioester group and R, R1, R2 and R3 are as defined in the specification, inhibit proliferation of tumor cells.

First hydroxamate inhibitors for carboxypeptidase A. N-acyl-N-hydroxy- β-phenylalanine S

A series of N-acyl-N-hydroxy-β-Phe were designed, synthesized, and shown to have potent inhibitory activity for carboxypeptidase A (CPA). They are the first examples of CPA inhibitors having a hydroxamate functionality.

Amino acid derivative

Derivatives having the general formula: STR1 in which the various radicals A,B,X,R1, R2, R3 and n have indicated definitions. These compounds have in particular enkephalinase-inhibiting, antalgic, antidepressive, antidiarrhea and hypotensive activities.

New bidentates as full inhibitors of enkephalin-degrading enzymes: Synthesis and analgesic properties

New compounds were designed to fully inhibit the in vitro metabolism of enkephalins, ensured by three different metallopeptidases. For this purpose, bidentate ligands as hydroxamate and N-hydroxy-N-formylamino groups were selected as highly potent metal coordinating agents and introduced on Phe-Gly and Phe-Ala related structures. Compounds corresponding to the general formula HC(O)N(OH)CH2CH(CH2Ph)CONHCH2COOH (compound 7) and HN(OH)C(O)CH2CH(CH2Ph)CONHCH(R)COOH (compound 11, R = H; compound 13, R = CH3) behave as full inhibitors of the three enzymes, with IC50's in the nanomolar range for enkephalinase, from 0.3 μM to 1 nM for dipeptidylaminopeptidase, and in the micromolar range for a biologically relevant aminopeptidase. Two diastereoisomers of the most active inhibitor 13 were separated by HPLC and their stereochemistry was assigned by 1H NMR spectroscopy. Both isomers were efficient as enkephalinase blockers, but only the RS isomer, designated kelatorphan, was able to strongly inhibit aminopeptidase and dipeptidylaminopeptidase. Intracerebroventricular injection in mice of these mixed inhibitors, especially kelatorphan, led to naloxone reversible analgesic responses (hot-plate test) that were slightly better than those produced by a mixture of thiorphan and bestatin, two potent inhibitors of enkephalinase and aminopeptidase, respectively. Kelatorphan was also more efficient in potentiating the analgesia induced by a subanalgesic dose of Met-enkephalin. All these results support a physiological role in pain transmission for enkephalinase and a probably synaptic aminopeptidase M.